Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9230966 | 0.81 | MAPT (0.42) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL5510041 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL854923 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL11421284 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL21844929 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL4288310 | 0.79 | ALDH1A1 (0.42) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL8064140 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL28363307 | 0.79 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNAMEN1KMT2A | |
| SCHEMBL306848 | 0.78 | HTT (0.50) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1811188 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1857443-B1 | Therapeutic morpholino-substituted compounds | ASTRAZENECA AB (SE) | 2012-03-28 | — | — | EP | claimed |
| JP-4820518-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| EP-1857443-A2 | Therapeutic morpholino-substituted compounds | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | claimed |
| US-6977255-B2 | Therapeutic morpholino-substituted compounds | KINACIA PTY. LTD. (AU) | 2005-12-20 | — | — | US | claimed |
| JP-2003530318-A | — | — | 2003-10-14 | — | — | JP | claimed |
| EP-1257537-A4 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD (AU) | 2003-04-23 | — | — | EP | claimed |
| EP-1257537-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | Kinacia Pty Ltd (AU) | 2002-11-20 | — | — | EP | claimed |
| WO-2001053266-A1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | KINACIA PTY LTD. (AU) | 2001-07-26 | — | — | WO | claimed |
| CN-117466803-A | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-111132976-B | Compounds, salts thereof and methods for treating diseases | 阿卡蒂亚药品公司 | 2023-08-22 | — | — | CN | disclosed |
| WO-2023141511-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| EP-3530663-B1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | SUNSHINE BIOPHARMA INC (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021003310-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | ALDH1A1 4554/4885MAPT 577/4885LMNA 3119/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ALDH1A1 623/4885MAPT 4279/4885LMNA 2744/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | ALDH1A1 623/4885MAPT 4279/4885LMNA 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.